中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

5 records (took 0.026 seconds)

    SYSTEMS AND METHODS FOR IDENTIFYING DIAGNOSTIC INDICATORS
    2.
    发明申请
    SYSTEMS AND METHODS FOR IDENTIFYING DIAGNOSTIC INDICATORS 审中-公开
    用于识别诊断指标的系统和方法

    公开(公告)号：WO2007059119A2

    公开(公告)日：2007-05-24

    申请号：PCT/US2006/044170

    申请日：2006-11-13

    Applicant: BOROZAN, Ivan ,  CHEN, Limin ,  EDWARDS, Aled, M. ,  HEATHCOTE, Elizabeth, J. ,  MCGILVRAY, Ian, D.

    Inventor： BOROZAN, Ivan ,  CHEN, Limin ,  EDWARDS, Aled, M. ,  HEATHCOTE, Elizabeth, J. ,  MCGILVRAY, Ian, D.

    IPC: C12Q1/68

    CPC classification number: C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  G06F19/18 ,  G06F19/20 ,  G06F19/24

    Abstract: Systems and methods are provided for predicting patient response to a therapy regimen for a liver disease or a disease that is treatable with an immunomodulatory disease therapy using gene expression classifiers. Systems and methods for screening for modulators of target gene expression are also provided. Systems and methods for developing therapeutics against one or more of the proteins coded for by genes of the present invention are also provided. Systems and methods for predicting a patient response to a regimen of interferon either alone or in conjuction with one or more therapeutic molecules, such as ribavirin, in a therapy for hepatitis C viral infection are also provided.

    Abstract translation: 提供了系统和方法，用于预测患者对用于使用基因表达分类器的免疫调节疾病治疗可治疗的肝病或疾病的治疗方案的反应。 还提供了用于筛选靶基因表达调节剂的系统和方法。 还提供了用于开发针对由本发明的基因编码的一种或多种蛋白质的治疗剂的系统和方法。 还提供了用于在丙型肝炎病毒感染的治疗中单独或与一种或多种治疗分子（例如利巴韦林）结合的患者对干扰素方案的预测的系统和方法。

    SYSTEMS AND METHODS FOR IDENTIFYING DIAGNOSTIC INDICATORS
    3.
    发明申请
    SYSTEMS AND METHODS FOR IDENTIFYING DIAGNOSTIC INDICATORS 审中-公开
    用于识别诊断指标的系统和方法

    公开(公告)号：WO2007059119A3

    公开(公告)日：2008-12-18

    申请号：PCT/US2006044170

    申请日：2006-11-13

    Applicant: BOROZAN IVAN ,  CHEN LIMIN ,  EDWARDS ALED M ,  HEATHCOTE ELIZABETH J ,  MCGILVRAY IAN D

    Inventor： BOROZAN IVAN ,  CHEN LIMIN ,  EDWARDS ALED M ,  HEATHCOTE ELIZABETH J ,  MCGILVRAY IAN D

    IPC: G01N33/48

    CPC classification number: C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  G06F19/18 ,  G06F19/20 ,  G06F19/24

    Abstract: Systems and methods are provided for predicting patient response to a therapy regimen for a liver disease or a disease that is treatable with an immunomodulatory disease therapy using gene expression classifiers. Systems and methods for screening for modulators of target gene expression are also provided. Systems and methods for developing therapeutics against one or more of the proteins coded for by genes of the present invention are also provided. Systems and methods for predicting a patient response to a regimen of interferon either alone or in conjuction with one or more therapeutic molecules, such as ribavirin, in a therapy for hepatitis C viral infection are also provided.

    Abstract translation: 提供了系统和方法，用于预测患者对用于使用基因表达分类器的免疫调节疾病治疗可治疗的肝病或疾病的治疗方案的反应。 还提供了用于筛选靶基因表达调节剂的系统和方法。 还提供了用于开发针对由本发明的基因编码的一种或多种蛋白质的治疗剂的系统和方法。 还提供了用于在丙型肝炎病毒感染的治疗中单独或与一种或多种治疗分子（例如利巴韦林）结合的患者对干扰素方案的预测的系统和方法。

    CRYSTAL STRUCTURE FOR RMLC AND USES THEREOF
    4.
    发明申请
    CRYSTAL STRUCTURE FOR RMLC AND USES THEREOF 审中-公开
    RMLC的晶体结构及其用途

    公开(公告)号：WO0179457A3

    公开(公告)日：2002-09-06

    申请号：PCT/CA0100512

    申请日：2001-04-12

    Applicant: UNIV HEALTH NETWORK ,  CHRISTENDAT DINESH ,  EDWARDS ALED M ,  PAI EMIL F ,  BOCHKAREV ALEXEI ,  SARIDAKIS VIVIAN

    Inventor： CHRISTENDAT DINESH ,  EDWARDS ALED M ,  PAI EMIL F ,  BOCHKAREV ALEXEI ,  SARIDAKIS VIVIAN

    IPC: C12N9/90 ,  C12Q1/533

    CPC classification number: C12N9/90

    Abstract: The invention provides the crystal structure of Methanobacterium thermoautotrophicum RmlC (MT RmlC) and identifies the active site thereof. The crystal structure can be used to determine the crystal structure of homologues, analogues, mutants and co-complexes of MT RmlC and to identify and design inhibitors to RmlC. The present invention has applicability in identifying and designing anti-bacterial agents and the treatment of bacterial infections.

    Abstract translation: 本发明提供了甲醇杆菌RmlC（MT RmlC）的晶体结构，并鉴定了其活性位点。 晶体结构可用于确定MT RmlC的同系物，类似物，突变体和共配合物的晶体结构，并鉴定和设计RmlC抑制剂。 本发明适用于鉴定和设计抗菌剂和细菌感染的治疗。

Patent Agency Ranking